Get started
Author

Monika Semmrich

Observed names: M Semmrich, M. Semmrich, Semmrich, M.
Institution: BioInvent (Sweden)
ORCID: 0009-0007-9833-9772
Observed ORCID: 0009-0007-9833-9772
OpenAlex ID: A5013449455
IRF4 Transcription-Factor-Dependent CD103+CD11b+ Dendritic Cells Drive Mucosal T Helper 17 Cell Differentiation
2013 · Emma K. Persson, Heli Uronen-Hansson, et al. · Immunity · 616
PDF
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
2018 · Sarah L. Buchan, Lang Dou, et al. · Immunity · 167
PDF
Importance of integrin LFA-1 deactivation for the generation of immune responses
2005 · Monika Semmrich, Andrew Smith, et al. · The Journal of Experimental Medicine · 127
Integrin Subunit CD18 Is the T-Lymphocyte Receptor for the Helicobacter pylori Vacuolating Cytotoxin
2008 · Xaver Sewald, Bettina Gebert-Vogl, et al. · Cell Host & Microbe · 122
PDF
RhoH is important for positive thymocyte selection and T-cell receptor signaling
2006 · Tatjana Dorn, Ursula Kuhn, et al. · Blood · 89
Directed antigen targeting in vivo identifies a role for CD103+ dendritic cells in both tolerogenic and immunogenic T-cell responses
2011 · M Semmrich, M Plantinga, et al. · Mucosal Immunology · 80
PDF
Design and Synthesis of Potent and Selective α4β7Integrin Antagonists
2001 · Jürgen Boer, Dirk Gottschling, et al. · Journal of Medicinal Chemistry · 40
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
2022 · Monika Semmrich, Jean-Baptiste Marchand, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
Domain binding and isotype dictate the activity of anti-human OX40 antibodies
2020 · Jordana Griffiths, Khiyam Hussain, et al. · Journal for ImmunoTherapy of Cancer · 31
PDF
A bispecific IgG format containing four independent antigen binding sites
2020 · Anne Ljungars, Torbjörn Schiött, et al. · Scientific Reports · 12
PDF
725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
2020 · Linda Mårtensson, Mathilda Kovacek, et al. · Journal for ImmunoTherapy of Cancer · 9
Abstract 936: Targeting TNFR2 for cancer immunotherapy: Ligand blocking depletors versus receptor agonists
2020 · Linda Mårtensson, Kirstie Cleary, et al. · Cancer Research · 9
594 BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
2020 · Monika Semmrich, Jean-Baptiste Marchand, et al. · Journal for ImmunoTherapy of Cancer · 6
Abstract 5602: BT-001, an oncolytic vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
2020 · Jean-Baptiste Marchand, Monika Semmrich, et al. · Cancer Research · 5
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al. · Cancer Research · 3
Abstract 4156: BI-1808 - a first in class ligand-blocking αTNFR2 antibody for cancer immunotherapy
2022 · Linda Mårtensson, Kirsty Cleary, et al. · Cancer Research · 3
Intact LFA-1 deactivation promotes T-cell activation and rejection of cardiac allograft
2009 · Norbert Hüser, Annette Fasan, et al. · International Immunology · 3
1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
2024 · S. Champiat, C. Lebbe, et al. · Annals of Oncology · 2
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy
2023 · Linda Martensson, Petra Holmkvist, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al. · Cancer Immunology Research · 1
PDF
Abstract 3567: Comprehensive preclinical studies of BT-001: An oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
2022 · Jean-Baptiste Marchand, Monika Semmrich, et al. · Cancer Research · 1
746 Vectorized Treg-depleting anti-CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
2021 · Monika Semmrich, Jean-Baptiste Marchand, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Works count: 54
Citation count: 1,363
H-index: 10
I10-index: 10
Year
Topic
Type